RAAS inhibitors and cardiovascular protection in large scale trials

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Cardiovascular diseases (CVD), including hypertension, coronary artery disease, and heart failure, are leading causes of morbidity and mortality.
• The global rise in CVD is exacerbated by aging populations and the diabetes pandemic, highlighting the need for cardioprotective strategies.
• The renin-angiotensin-aldosterone system (RAAS) plays a critical role in regulating blood pressure, cardiovascular, and renal function.

Purpose of the Study:

• To review evidence from large clinical trials on cardioprotection achieved through blockade of the renin-angiotensin-aldosterone system (RAAS).
• To assess the efficacy of various RAAS-targeting drugs in preventing cardiovascular events and improving outcomes.

Main Methods:

• Review of large-scale clinical trials evaluating RAAS-blocking agents.
• Analysis of data on the cardioprotective effects of Angiotensin-converting enzyme inhibitors (ACEi), Ang-II receptor blockers (ARB), and mineralocorticoid receptor antagonists (MRA).
• Inclusion of emerging therapies like direct renin inhibitors and dual-acting RAAS blockers.

Main Results:

• RAAS blockade, through agents like ACEi, ARBs, and MRAs, has demonstrated significant cardioprotective benefits in numerous clinical trials.
• These agents, used singly or in combination, effectively reduce cardiovascular morbidity and mortality in patients with or at risk of CVD.
• Ongoing research is exploring novel RAAS-targeting drugs for enhanced cardioprotection.

Conclusions:

• RAAS blockade is a cornerstone of modern cardiovascular disease management, offering substantial cardioprotection.
• Targeting the RAAS is essential for managing hypertension, heart failure, and preventing future cardiovascular events.
• Continued investigation into RAAS-modulating therapies promises further advancements in cardiovascular care.